Transcat Buys Southeastern Biomedical to Expand Calibration Channel
TRNS sits 71% above its 52-week low of $50.23.
Summary
Transcat is acquiring Southeastern Biomedical, expanding its biomedical calibration channel. The deal follows strong fiscal Q1 2027 results reported earlier this month, with service revenue up 27.3% to $62.6M. The acquisition price was $12.8M, paid in cash, subject to certain customary adjustments and holdback provisions. This acquisition adds a new geographic or service capability in the biomedical calibration space, supporting Transcat's growth strategy. Watch for integration details and any impact on future service revenue growth.
At the time of this announcement, TRNS was trading at $85.84 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $803.5M. The 52-week trading range was $50.23 to $100.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.